IMNM vs. KYMR, IMVT, MOR, CRNX, ALVO, HCM, AMRX, CPRX, BHC, and OGN
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Immunome vs. Its Competitors
Immunome (NASDAQ:IMNM) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.
44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Kymera Therapeutics has a net margin of -409.07% compared to Immunome's net margin of -1,875.21%. Kymera Therapeutics' return on equity of -30.11% beat Immunome's return on equity.
Kymera Therapeutics has higher revenue and earnings than Immunome. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kymera Therapeutics had 6 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Kymera Therapeutics and 1 mentions for Immunome. Immunome's average media sentiment score of 1.87 beat Kymera Therapeutics' score of 0.78 indicating that Immunome is being referred to more favorably in the media.
Immunome presently has a consensus price target of $23.33, suggesting a potential upside of 170.06%. Kymera Therapeutics has a consensus price target of $59.11, suggesting a potential upside of 32.89%. Given Immunome's higher possible upside, equities analysts plainly believe Immunome is more favorable than Kymera Therapeutics.
Immunome has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Summary
Kymera Therapeutics beats Immunome on 11 of the 16 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 7/12/2025 by MarketBeat.com Staff
